| Name | Title | Contact Details |
|---|---|---|
Jesse Oropesa |
Executive Director, Legal | Profile |
Elizabeth Gorman |
Senior Vice President, Legal | Profile |
Todd Baumgartner |
Senior Vice President, Regulatory Affairs and Clinical Operations | Profile |
Andrew Mayer |
Senior Vice President and Deputy General Counsel | Profile |
JMCC Group is the leading global provider of premium quality, sustainably grown, Jamaican medical cannabis products and related services to customers around the world, including licensed producers, medical researchers, product developers, manufacturers and distributors.
Quad Five Materials Bio is a Ryegate, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Helsinn Therapeutics (US) is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for five additional years of QIDP market exclusivity in the event of U.S. approval. It is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient`s own T cells harvested from the patient`s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells.